Project Grant R01CA316736
Award Date 8/12/26
Completion Date 7/31/31
Dollars Obligated $683K
Federal Agency
Federal Grant Program
Assistance Type
Project Grant
Place of Performance
San Francisco, CA 94143, USA
Similar Awards
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $172,889 on January 12, 2026, under the Cancer Research Manpower program (CFDA 93.398) to develop and optimize chimeric antigen receptor (CAR) T-cell therapies for acute myeloid leukemia (AML). The funded research applies structure-guided protein evolution to improve natural ligand-based CAR-T therapies targeting CD70 in AML. The project uses computational deep learning algorithms and high-throughput...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $680,597 on April 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to conduct genome-wide in vivo CRISPR screens in human T cells identifying G protein-coupled receptor pathway targets to enhance CAR-T therapies for solid tumors. The work develops and applies a novel screening platform enabling large-scale genetic screens in human CD4+ and CD8+ T cells within tumor xenografts. Prior...
- The National Cancer Institute awarded the University of California, San Diego $663,998 on July 13, 2026, under the Cancer Treatment Research program (CFDA 93.395) to conduct mechanistic research on targeting the Type I interferon pathway to improve cancer therapy efficacy. The research investigates how ubiquitin specific protease 18 (USP18) negatively regulates interferon signaling in cancer cells and tests whether blocking USP18-mediated suppression of the interferon response can enhance the...
- Federal Grant Award Summary The National Cancer Institute (NCI) awarded a $421,685 Project Grant to The Regents of the University of California, San Francisco under the Cancer Biology Research program (CFDA 93.396) for research activities spanning August 8, 2025 through July 31, 2027. This award funds a discovery-focused research initiative investigating functional immune niches within the tumor microenvironment (TME) that support effective cancer immunotherapy responses. The primary deliverable...
- The National Cancer Institute awarded Sloan-Kettering Institute for Cancer Research $452,540 on May 1, 2026, under the Cancer Biology Research program (CFDA 93.396) to investigate the innate and adaptive immune determinants of cytokine release syndrome (CRS) following chimeric antigen receptor (CAR) T cell therapy. CRS occurs in approximately 93 percent of patients receiving CAR T cell therapy, manifesting as fever, hypotension, hypoxia, and dyspnea due to rapid increases in multiple cytokines...
- The National Institutes of Health National Cancer Institute awarded the University of California, San Diego $771,811 on June 1, 2026, under the Cancer Treatment Research program (CFDA 93.395) to identify small molecule activators of type I interferon signaling for cancer treatment. The research focuses on discovering and developing small molecule inhibitors targeting USP18, a ubiquitin protease that suppresses the type I interferon response through negative feedback regulation. Prior work...
- The National Cancer Institute, part of the Department of Health and Human Services National Institutes of Health, awarded $278,197 to The Regents of the University of California, San Francisco on July 20, 2026, under the Cancer Research Manpower program (CFDA 93.398, Project Grant K08CA297137). The award funds development of next-generation cellular therapies targeting acute myeloid leukemia, specifically engineered CAR-T cells and multifunctional anti-CD70 T cell therapies designed to eliminate...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $635,782 on August 12, 2026, under the Cancer Treatment Research program (CFDA 93.395) to establish a co-clinical imaging framework for defining noninvasive biomarkers of therapy-induced cardiotoxicity. The project combines hyperpolarized 13C MRI to quantify pyruvate dehydrogenase, lactate dehydrogenase, and alanine aminotransferase fluxes; 31P MR spectroscopic imaging to measure...
- The National Cancer Institute awarded the University of California, Los Angeles $653,568 on July 1, 2026, through the Cancer Treatment Research program (CFDA 93.395) to conduct research on enhancing antitumor immunity through pharmacologic modulation of T-cell-mediated cytotoxicity. The research addresses a bottleneck in immunotherapy: naturally occurring T cells targeting tumor-associated antigens or neoantigens often exhibit low to intermediate affinity and weak antitumor activity, and...
- The National Cancer Institute awarded The Regents of the University of California, San Francisco $700,338 on May 11, 2026, under the Cancer Treatment Research program (CFDA 93.395) to define and override mechanisms of in vitro and clinical resistance to asciminib, the first highly active allosteric kinase inhibitor for chronic myeloid leukemia. The research addresses acquired resistance to asciminib, which is rapidly being adopted as frontline therapy for CML patients. The project will employ...